Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
BioPhotonics article on how QPI advances Regenerative Medicine (Issue 07/08 2023)
The BioPhotonics July/August 2023 issue holds a feature article by PHI highlighting how HoloMonitor’s quantitative phase imaging (QPI) technology has the potential to propel regenerative medicine forward.
BioStock: PHI charts a bold course to impact regenerative medicine
BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
BioStock: The five best life science stocks of the first half-year
PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
Applied Sciences Special Issue: Novel Approaches of Digital Holographic Microscopy in Cell Biology
PHI CSO Kersti Alm invites you to join this Applied Sciences Special Issue highlighting Digital Holographic Microscopy in Cell Biology.
European Patent Office intends to grant PHI patent on synthetic antibodies
PHI AB announces today that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies.
PHI visit WFIRM – Inside the World of Regenerative Medicine
PHI headed to the Wake Forest Institute for Regenerative Medicine (WFIRM) in Winston-Salem to visit, collaborate and attend the World Stem Cell Summit 2023.
HoloMonitor M4FL in the spotlight at EACR and ISSCR 2023
Recapping the scientific conferences EACR and ISSCR 2023 that put HoloMonitor M4FL in the spotlight at its world premiere.
BioStock: PHI’s CEO reflects on global roadshow success
BioStock contacted CEO Patrik Eschricht to learn about the team’s achievements on their global roadshow this early summer.
BIOSpektrum application article highlights HoloMonitor technology (in German)
PHI’s CSO, Kersti Alm, and Head of Communication, Lisa Bodily, have recently contributed to the June 2023 issue of the German BIOSpektrum journal. Their application article sheds light on how HoloMonitor’s technology is applied for non-invasive live cell analysis.
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.